UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
biological and medical sciences (9138) 9138
medical sciences (9029) 9029
pharmacology. drug treatments (8910) 8910
psychology. psychoanalysis. psychiatry (8848) 8848
neuropharmacology (8836) 8836
psychopharmacology (8792) 8792
psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (8760) 8760
science & technology (7934) 7934
life sciences & biomedicine (7864) 7864
male (6974) 6974
animals (6678) 6678
humans (4618) 4618
neurosciences & neurology (4531) 4531
neurosciences (4358) 4358
rats (4224) 4224
pharmacology & pharmacy (4070) 4070
psychiatry (2923) 2923
female (2868) 2868
psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer (2736) 2736
adult (1945) 1945
rats, sprague-dawley (1624) 1624
dose-response relationship, drug (1587) 1587
mice (1529) 1529
middle aged (1364) 1364
psychopathology. psychiatry (1357) 1357
brain - metabolism (1333) 1333
brain - drug effects (1248) 1248
nootropic agents - pharmacology (1183) 1183
adult and adolescent clinical studies (1153) 1153
time factors (1030) 1030
rats, wistar (993) 993
neurology (973) 973
fundamental and applied biological sciences. psychology (967) 967
depression (960) 960
antidepressants (922) 922
clinical neurology (915) 915
disease models, animal (903) 903
motor activity - drug effects (892) 892
antidepressive agents - pharmacology (878) 878
dopamine - metabolism (864) 864
aged (854) 854
behavior, animal - drug effects (847) 847
rats, inbred strains (809) 809
hippocampus - drug effects (756) 756
serotonin - metabolism (751) 751
mood disorders (736) 736
dopamine (721) 721
nootropic agents - therapeutic use (707) 707
alzheimer's disease (705) 705
brain (649) 649
in vitro techniques (640) 640
hippocampus - metabolism (639) 639
alzheimer disease - drug therapy (634) 634
analysis of variance (633) 633
neurons - drug effects (629) 629
cocaine (599) 599
drug interactions (594) 594
depressive disorder - drug therapy (582) 582
biochemistry & molecular biology (580) 580
serotonin (576) 576
kinetics (572) 572
analysis (568) 568
antidepressive agents - therapeutic use (553) 553
double-blind method (541) 541
treatment outcome (539) 539
behavioral sciences (518) 518
pharmacology/toxicology (515) 515
serotonin uptake inhibitors - pharmacology (510) 510
antidepressant (496) 496
cocaine - pharmacology (477) 477
biomedicine (471) 471
neurons - metabolism (471) 471
mice, inbred c57bl (468) 468
chemistry, medicinal (463) 463
rodents (452) 452
adolescent (449) 449
vertebrates: nervous system and sense organs (444) 444
norepinephrine - metabolism (430) 430
drug administration schedule (429) 429
cerebral cortex - metabolism (424) 424
central nervous system stimulants - pharmacology (422) 422
hippocampus (422) 422
research (420) 420
fluoxetine - pharmacology (412) 412
corpus striatum - metabolism (410) 410
toxicology (408) 408
microdialysis (406) 406
chemistry (404) 404
cognition - drug effects (403) 403
drug therapy (401) 401
corpus striatum - drug effects (400) 400
brain chemistry - drug effects (398) 398
maze learning - drug effects (392) 392
cerebral cortex - drug effects (390) 390
physical sciences (386) 386
abridged index medicus (385) 385
memory - drug effects (383) 383
depression, mental (381) 381
structure-activity relationship (380) 380
methamphetamine (379) 379
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (10618) 10618
Japanese (91) 91
Russian (75) 75
German (16) 16
Chinese (8) 8
Spanish (8) 8
French (5) 5
Hungarian (5) 5
Italian (3) 3
Portuguese (3) 3
Czech (1) 1
Dutch (1) 1
Finnish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature reviews. Drug discovery, ISSN 1474-1776, 2014, Volume 13, Issue 6, pp. 433 - 444
Pharmacology & Pharmacy | Life Sciences & Biomedicine | Biotechnology & Applied Microbiology | Science & Technology | Intestines - drug effects | Intestinal Mucosa - metabolism | Drugs, Investigational - pharmacology | Humans | Drugs, Investigational - therapeutic use | Orphan Nuclear Receptors - metabolism | Brain - metabolism | Drugs, Investigational - chemistry | Protein Isoforms - metabolism | Liver - drug effects | Alzheimer Disease - prevention & control | Liver X Receptors | Drug Design | Neurons - metabolism | Hypolipidemic Agents - chemistry | Drug Evaluation, Preclinical | Neurons - drug effects | Hypolipidemic Agents - adverse effects | Nerve Tissue Proteins - antagonists & inhibitors | Molecular Targeted Therapy - adverse effects | Atherosclerosis - drug therapy | Liver - metabolism | Alzheimer Disease - drug therapy | Nootropic Agents - therapeutic use | Clinical Trials as Topic | Hypolipidemic Agents - pharmacology | Nootropic Agents - adverse effects | Nootropic Agents - chemistry | Drug Discovery | Atherosclerosis - metabolism | Brain - drug effects | Nerve Tissue Proteins - metabolism | Orphan Nuclear Receptors - antagonists & inhibitors | Animals | Signal Transduction - drug effects | Alzheimer Disease - metabolism | Lipid Metabolism - drug effects | Hypolipidemic Agents - therapeutic use | Atherosclerosis - prevention & control | Nootropic Agents - pharmacology | Protein Isoforms - antagonists & inhibitors | Care and treatment | Research | Drug discovery | Patient outcomes | Risk factors | Atherosclerosis | Index Medicus
Journal Article
Biochemical pharmacology, ISSN 0006-2952, 09/2017, Volume 139, pp. 40 - 55
Covalent mechanisms | Non-covalent mechanisms | Amyloid inhibitor | Natural products | Inhibition mechanisms | Amyloidosis - prevention & control | Drugs, Investigational - pharmacology | Antioxidants - chemistry | Nootropic Agents - metabolism | Antioxidants - metabolism | Healthy Diet | Humans | Polyphenols - pharmacology | Drugs, Investigational - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - chemistry | Biological Products - pharmacology | Flavonoids - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Polyphenols - metabolism | Amyloidogenic Proteins - antagonists & inhibitors | Drugs, Investigational - chemistry | Protein Aggregation, Pathological - prevention & control | Amyloidosis - diet therapy | Drug Design | Flavonoids - pharmacology | Protein Aggregation, Pathological - diet therapy | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Chelating Agents - therapeutic use | Biological Products - therapeutic use | Chelating Agents - chemistry | Nootropic Agents - therapeutic use | Amyloidosis - drug therapy | Antioxidants - pharmacology | Chelating Agents - pharmacology | Nootropic Agents - chemistry | Drug Discovery | Protein Aggregation, Pathological - drug therapy | Amyloidogenic Proteins - metabolism | Antioxidants - therapeutic use | Biological Products - chemistry | Animals | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Flavonoids - metabolism | Polyphenols - chemistry | Biological Products - metabolism | Polyphenols - therapeutic use | Chelating Agents - metabolism | Dietary Supplements | Flavonoids - chemistry | Amyloidosis - metabolism | Nootropic Agents - pharmacology | Medicine, Experimental | Medical research | Nervous system diseases | Glycoproteins | Drug discovery | Index Medicus
Journal Article
Science (American Association for the Advancement of Science), ISSN 0036-8075, 9/2010, Volume 329, Issue 5998, pp. 1537 - 1541
Receptors | MicroRNA | Serotonin agents | Neurons | Antidepressants | Serotonin receptors | REPORTS | Cell lines | Serotonin plasma membrane transport proteins | Adrenergic neurons | Locus coeruleus | Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer | Psychology. Psychoanalysis. Psychiatry | Psychopharmacology | Pharmacology. Drug treatments | Biological and medical sciences | Medical sciences | Neuropharmacology | Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) | Up-Regulation | Protein Biosynthesis | Humans | MicroRNAs - metabolism | Nerve Growth Factors - metabolism | Antidepressive Agents, Second-Generation - administration & dosage | Raphe Nuclei - metabolism | Serotonin Plasma Membrane Transport Proteins - genetics | Neurons - metabolism | 3' Untranslated Regions | Neurons - drug effects | Serotonin Uptake Inhibitors - metabolism | Cell Line | Fluoxetine - pharmacology | S100 Calcium Binding Protein beta Subunit | MicroRNAs - administration & dosage | Depression | S100 Proteins - metabolism | Antidepressive Agents, Second-Generation - pharmacology | Serotonin Plasma Membrane Transport Proteins - metabolism | Animals | Norepinephrine - metabolism | Raphe Nuclei - drug effects | Serotonin Uptake Inhibitors - administration & dosage | Serotonin - metabolism | Fluoxetine - administration & dosage | Fluoxetine - metabolism | Mice | MicroRNAs - genetics | HeLa Cells | Antidepressive Agents, Second-Generation - metabolism | Serotonin Uptake Inhibitors - pharmacology | Locus Coeruleus - metabolism | Pharmacogenetics | Serotonin | Physiological aspects | Serotonin uptake inhibitors | Dosage and administration | Research | Health aspects | Pharmacology | Index Medicus
Journal Article
Journal of medicinal chemistry, ISSN 0022-2623, 2/2008, Volume 51, Issue 3, pp. 347 - 372
Pharmacology & Pharmacy | Life Sciences & Biomedicine | Chemistry, Medicinal | Science & Technology | Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer | Neurology | Psychology. Psychoanalysis. Psychiatry | Psychopharmacology | Pharmacology. Drug treatments | Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases | Biological and medical sciences | Medical sciences | Neuropharmacology | Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) | Antioxidants - chemistry | Humans | Calcium Channel Blockers - therapeutic use | Cholinesterase Inhibitors - chemistry | Parkinson Disease - drug therapy | Neurodegenerative Diseases - drug therapy | Alzheimer Disease - pathology | Neurofibrillary Tangles - metabolism | Amyloid beta-Peptides - metabolism | Parkinson Disease - metabolism | Huntington Disease - drug therapy | Binding Sites | Chelating Agents - therapeutic use | Multiple Sclerosis - metabolism | Neurofibrillary Tangles - pathology | Neurodegenerative Diseases - pathology | Plaque, Amyloid - pathology | Chelating Agents - chemistry | Neurotransmitter Agents - metabolism | Alzheimer Disease - drug therapy | Antioxidants - pharmacology | Chelating Agents - pharmacology | Neurodegenerative Diseases - metabolism | Calcium Channel Blockers - pharmacology | Huntington Disease - metabolism | Antioxidants - therapeutic use | Cholinesterase Inhibitors - pharmacology | Alzheimer Disease - metabolism | Calcium Channel Blockers - chemistry | Ligands | Plaque, Amyloid - metabolism | Cholinesterase Inhibitors - therapeutic use | Acetylcholinesterase - metabolism | Multiple Sclerosis - drug therapy | Index Medicus
Journal Article
British journal of nutrition, ISSN 0007-1145, 01/2015, Volume 113, Issue 2, pp. 350 - 365
Behaviour, Appetite and Obesity | Full Papers | Well-being | Serotonin | LumiVida | Tryptophan | Depression | Cognition | Emotion | Life Sciences & Biomedicine | Nutrition & Dietetics | Science & Technology | Protein Hydrolysates - metabolism | Stress, Psychological - prevention & control | Nootropic Agents - metabolism | Humans | Middle Aged | Reaction Time | Antidepressive Agents - metabolism | Tryptophan - metabolism | Cognitive Dysfunction - prevention & control | Mental Fatigue - metabolism | Sleep Wake Disorders - metabolism | Depression - metabolism | Egg Proteins, Dietary - adverse effects | Psychiatric Status Rating Scales | Mental Fatigue - prevention & control | Tryptophan - blood | Stress, Psychological - metabolism | Egg Proteins, Dietary - therapeutic use | Female | Dietary Supplements - adverse effects | Beverages | Egg Proteins, Dietary - metabolism | Antidepressive Agents - blood | Serotonin Agents - therapeutic use | Protein Hydrolysates - therapeutic use | Double-Blind Method | Stress, Psychological - blood | Cognitive Dysfunction - metabolism | Nootropic Agents - therapeutic use | Cognitive Dysfunction - blood | Nootropic Agents - blood | Nootropic Agents - adverse effects | Protein Hydrolysates - adverse effects | Serotonin Agents - metabolism | Serotonin Agents - adverse effects | Antidepressive Agents - therapeutic use | Mental Fatigue - blood | Depression - prevention & control | Energy Metabolism | Sleep Wake Disorders - blood | Sleep Wake Disorders - prevention & control | Tryptophan - adverse effects | Aged | Serotonin Agents - blood | Antidepressive Agents - adverse effects | Tryptophan - therapeutic use | Cohort Studies | Depression - blood | Amino acids | Emotional disorders | Cognition & reasoning | Dietary supplements | Index Medicus
Journal Article
Neuropsychopharmacology (New York, N.Y.), ISSN 0893-133X, 11/2010, Volume 35, Issue 12, pp. 2378 - 2391
neurogenesis | dentate gyrus | depression | serum | neurotrophic factor | antidepressant | Pharmacology & Pharmacy | Neurosciences | Neurosciences & Neurology | Life Sciences & Biomedicine | Psychiatry | Science & Technology | Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer | Psychology. Psychoanalysis. Psychiatry | Adult and adolescent clinical studies | Psychopharmacology | Pharmacology. Drug treatments | Psychopathology. Psychiatry | Mood disorders | Biological and medical sciences | Depression | Medical sciences | Neuropharmacology | Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) | Anti-Anxiety Agents - metabolism | Recombinant Proteins - therapeutic use | Male | Anxiety - drug therapy | Extracellular Signal-Regulated MAP Kinases - metabolism | Hippocampus - drug effects | Antidepressive Agents - metabolism | Corpus Striatum - metabolism | Depression - drug therapy | Brain-Derived Neurotrophic Factor - pharmacology | Antidepressive Agents - pharmacology | Brain-Derived Neurotrophic Factor - metabolism | Neurogenesis - drug effects | Anti-Anxiety Agents - therapeutic use | Brain-Derived Neurotrophic Factor - therapeutic use | Disease Models, Animal | Recombinant Proteins - metabolism | Mice, Inbred C57BL | Anti-Anxiety Agents - pharmacology | Recombinant Proteins - pharmacology | Recombinant Proteins - administration & dosage | Infusions, Subcutaneous | Antidepressive Agents - therapeutic use | Brain-Derived Neurotrophic Factor - administration & dosage | Hippocampus - metabolism | Animals | Cyclic AMP Response Element-Binding Protein - metabolism | Corpus Striatum - drug effects | Mice | Mice, Inbred BALB C | Index Medicus | biological psychiatry | animal models | bipolar | unipolar | molecular and cellular neurobiology | Original
Journal Article